Filing Flows › Jaguar Health (JAGX) › Q2 2026
Jaguar Health (JAGX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 19, 2026
Jaguar Health (JAGX) reported revenue of $1.2M for the second quarter 2026 (Q2 2026), -59% from a year earlier and -94% from the quarter before. Operating margin was -620.2%.
Jaguar Health, Q2 2026: revenue $1.2M (-59% year over year), operating margin -620.2%, net loss $12.8M, operating cash flow −$5.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | -94% | -59% |
| Operating profit | −$7.6M | -175% | — |
| Net earnings | −$12.8M | -247% | — |
| Operating cash flow | −$5.3M | -160% | — |
What changed
Revenue was $1.2M in Q2 2026, down 59% year over year and down 94% from the previous quarter. Product was the largest line at 96% of revenue. Product lost $1.8M year over year (down 60%), 100% of the total change.
Operating costs exceeded revenue by $7.6M, an operating margin of -620.2%. Total costs fell 20% while revenue fell 59%. The fastest-growing cost line was Cost of revenue (+96%). The quarter ended with a net loss of $12.8M, after a profit of $8.7M the previous quarter. Minority interests bore $101K of it: to shareholders the quarter was a loss of $12.7M.
Operating cash flow was −$5.3M. Non-cash charges added back $473K of depreciation and amortization and $171K of share-based compensation. Working capital and other items added $6.8M.
Questions
What was Jaguar Health's revenue in the second quarter 2026?
Jaguar Health (JAGX) reported revenue of $1.2M for the second quarter 2026 (Q2 2026), -59% from a year earlier and -94% from the quarter before.
Was Jaguar Health profitable in the second quarter 2026?
Operating loss was $7.6M (-620.2% of revenue) and net loss $12.8M.
Source: Jaguar Health 10-Q on SEC EDGAR.